Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Scholar Rock Holding Corp (SRRK)
NASDAQ:SRRK
RESEARCH TOOLSreports
Holding SRRK?
Track your performance easily
SRRK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.76 - $43.38
Previous Close$39.9
Volume839.72K
Average Volume (3M)2.06M
Market Cap
$3.74B
Enterprise Value$3.66B
Total Cash (Recent Filing)$139.06M
Total Debt (Recent Filing)$66.61M
Price to Earnings (P/E)―
Beta2.01
Next Earnings
Mar 11, 2025EPS Estimate
-$0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.47
Shares Outstanding93,614,951
10 Day Avg. Volume884,039
30 Day Avg. Volume2,057,793
Standard Deviation0.43
R-Squared0.00332
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)32.78
Price to Sales (P/S)2006.24
Price to Cash Flow (P/CF)-12.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.82K
Enterprise Value/Gross Profit1.83K
Enterprise Value/Ebitda-16.54
Forecast
1Y Price Target
$40.57Price Target Upside1.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Scholar Rock Holding News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessSRRK reported positive Phase III data for its anti-myostatin drug in SMA with clinically meaningful efficacy and excellent safety.
Market PositioningCompetitor Phase 2 Trial Failure Opens Up The Field for SRRK, making it a more attractive option in the SMA market.
Regulatory ProgressScholar Rock remains on track to submit a U.S. Biologics License Application and a European Union marketing authorization application in the first quarter of 2025.
Bears Say
Clinical TrialsPhase III study of taldefgrobep alfa did not demonstrate significant improvement on the primary endpoint.
Investor SentimentInvestors express apprehension regarding upcoming Phase III data on taldefgrobep alfa.
Market CompetitionSMA data from a competitor may negatively impact Scholar Rock Holding's market position.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SRRK FAQ
What was Scholar Rock Holding Corp’s price range in the past 12 months?
Scholar Rock Holding Corp lowest stock price was $6.76 and its highest was $43.38 in the past 12 months.
What is Scholar Rock Holding Corp’s market cap?
Currently, no data Available
When is Scholar Rock Holding Corp’s upcoming earnings report date?
Scholar Rock Holding Corp’s upcoming earnings report date is Mar 11, 2025 which is in 80 days.
How were Scholar Rock Holding Corp’s earnings last quarter?
Scholar Rock Holding Corp released its earnings results on Nov 12, 2024. The company reported -$0.66 earnings per share for the quarter, missing the consensus estimate of -$0.58 by -$0.08.
Is Scholar Rock Holding Corp overvalued?
According to Wall Street analysts Scholar Rock Holding Corp’s price is currently Undervalued.
Does Scholar Rock Holding Corp pay dividends?
Scholar Rock Holding Corp does not currently pay dividends.
What is Scholar Rock Holding Corp’s EPS estimate?
Scholar Rock Holding Corp’s EPS estimate is -$0.6.
How many shares outstanding does Scholar Rock Holding Corp have?
Scholar Rock Holding Corp has 93,614,950 shares outstanding.
What happened to Scholar Rock Holding Corp’s price movement after its last earnings report?
Scholar Rock Holding Corp reported an EPS of -$0.66 in its last earnings report, missing expectations of -$0.58. Following the earnings report the stock price went down -5.293%.
Which hedge fund is a major shareholder of Scholar Rock Holding Corp?
Among the largest hedge funds holding Scholar Rock Holding Corp’s share is Fisher Asset Management LLC. It holds Scholar Rock Holding Corp’s shares valued at 6M.
---
Scholar Rock Holding Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.57 (1.68% Upside)
$40.57 (1.68% Upside)
Blogger Sentiment
Bullish
SRRK Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 638.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $15.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.1%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
230.02%
12-Months-Change
Fundamentals
Return on Equity
-183.07%
Trailing 12-Months
Asset Growth
-28.54%
Trailing 12-Months
Company Description
Scholar Rock Holding Corp
Scholar Rock Holding Corp. is a biopharmaceutical company, which engages in the development and discovery of innovative medicines. The company offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
---
SRRK Earnings Call
Q3 2024
0:00 / 0:00
---
SRRK Stock 12 Month Forecast
Average Price Target
$40.57
▲(1.68% Upside)
Technical Analysis
Best Analysts Covering SRRK
1 Year
1 Year Success Rate
9/10 ratings generated profit
1 Year Average Return
+100.13%
assigned a buy rating 26 days ago
Copying Srikripa Devarakonda's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +100.13% per trade.
---